Skip to main content
TipRanks
Go Ultimate75% OFF

Progyny (PGNY) Q3 2026 Earnings Report

712 Followers

PGNY Q3 2026 EPS Results

Actual EPS
$0.32
Consensus EPS
$0.31
Beat/Miss
Beat by +$0.01
One Year Ago EPS
$0.15

PGNY Q3 2026 Revenue Results

Actual Revenue
$341.25M
Expected Revenue
$340.76M
Beat/Miss
Beat by +$493.00K
YoY Revenue Growth
+8.91%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
After Close
Conference Call
Wednesday, November 4, 2026
PGNY Upcoming Earnings

Progyny's next earnings date is estimated for March 1, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

PGNY Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:21.96%|
Earnings Call Sentiment|Positive

The call was strongly positive, with record new-client and covered-life additions, near 100% retention, healthy utilization, improved gross margins, strong cash generation, significant share repurchases and raised full-year guidance. The main challenges were a modest year-over-year decline in adjusted EBITDA margin, temporary third-quarter seasonality, elevated medical cost inflation and the currently immaterial contribution from Progyny Select.

Company Guidance

For full year 2026, Progyny is now projecting revenue of between $1.365 billion to $1.385 billion, reflecting growth of 5.9% to 7.5%; excluding the $48.5 million in revenue from the client who is under a transition of care agreement over the first half of 2025, full year revenue growth is projected to be 10.1% to 11.7%. Adjusted EBITDA is expected to be $235 million to $240 million, net income $107 million to $110.6 million, earnings per diluted share $1.30 and $1.35, and adjusted EPS $2.09 and $2.13 on the basis of approximately 82 million fully diluted shares. For the fourth quarter, revenue is expected to be $344.7 million to $364.7 million, for growth of 8.3% to 14.6%, adjusted EBITDA between $57.9 million to $62.9 million, net income between $28.5 million to $32.1 million, earnings per diluted share $0.36 and $0.41, and adjusted EPS $0.53 and $0.58 on the basis of 79 million fully diluted shares; at the midpoint of ranges for both the quarter and the year, the company expects to maintain a consistent adjusted EBITDA margin. The majority of the over 85 clients and 1.3 million lives added in the most recent selling season are expected to go live in the first quarter of 2027, with a meaningful number of lives, several hundred thousand, give or take, expected to launch midyear; once all the new clients are live in 2027, Progyny anticipates having more than 660 clients, representing 8.3 million covered lives.

  • Record Third-Quarter Revenue and ProfitabilityProgyny reported record revenue and profitability for the third quarter. Revenue was above the midpoint of guidance and increased nearly 9% versus 2025.
  • Strong Nine-Month Revenue GrowthRevenue increased 11% during the first nine months of the year when excluding the contribution from a former large client under a transition-of-care agreement through the first half of 2025.
  • Record Selling SeasonThe most recent selling season generated a record 1.3 million new covered lives and more than 85 new clients, including several prestigious universities, a Mag 7 technology leader, one of the largest U.S. banks and the nation's largest health benefit fund for public employees.
  • Broad and Diversified New Client CohortNew clients range from approximately 1,000 to well in excess of 100,000 covered lives. Progyny expects to enter 2027 with its most diverse client base ever, with no single economic sector or client making an outsized contribution.
  • Near-Complete Client Retention and ExpansionThe company achieved another year of near 100% retention of its existing client base. Approximately 20% of existing clients committed to adding to their solution for 2027, generally in line with the prior couple of years.
  • Strong Pharmacy and Expanded Product AdoptionAmong new clients, Progyny achieved a near 100% attach rate for its pharmacy program. The company expects approximately 95% to 96% of clients to have Rx coverage next year, and more than 3 million lives are expected to have expanded products during 2027.
  • Growing Sales Pipeline for 2027Management said the active pipeline for the 2027 selling season is larger than it was at the same point last year and is the biggest it has ever been, including multiple large and jumbo-account opportunities.
  • Healthy Member Engagement and UtilizationMember engagement remained within long-established ranges, with utilization trending toward the higher end of those ranges in the third quarter. Management said engagement remained healthy entering the fourth quarter and that visibility was good for October and November.
  • Gross Margin Expansion and Care Management EfficienciesGross margin expanded by 130 basis points year over year, driven by a reduction in stock compensation expense and continued efficiencies in care management delivery. Over a three-year period, management said costs had increased only 1% to 2% per year.
  • Profitability Maintained During Investment CycleTrailing twelve-month adjusted EBITDA margin was 17.1%, consistent with its trend during the period of increased investment. Management said this demonstrated the ability to invest for growth without resetting overall profitability levels.
  • Continued Investment in Products and InfrastructureProgyny continues to invest in expanding its product platform, adding member-experience features and laying the foundation for future growth. Year-to-date capital expenditures were approximately $9 million higher than in the first three quarters of 2025 but remained approximately 2% of revenue.
  • Strong Operating Cash Flow and ConversionThe company generated more than $56 million of operating cash flow in the quarter and $207 million on a trailing twelve-month basis. It exceeded $200 million of trailing twelve-month operating cash flow for seven consecutive quarters and continued to meet or exceed its 75% adjusted EBITDA-to-operating-cash-flow conversion target.
  • Improved Days Sales Outstanding and Strong LiquidityDays sales outstanding ended the quarter at just under 66 days, nearly seven days lower than the year-ago period. Total working capital was $224 million, including $196 million in cash, cash equivalents and marketable securities, with no borrowings and no debt.
  • Meaningful Share RepurchasesProgyny repurchased nearly 3 million shares during the third quarter for approximately $83 million. Since the latest authorization began, it has repurchased nearly 5.5 million shares, and across the current and prior programs it has purchased more than 14 million shares since last November, reducing shares outstanding by nearly 15% over the past year.
  • Raised Full-Year GuidanceThe company raised the midpoint of its full-year 2026 guidance. Revenue is expected to be $1.365 billion to $1.385 billion, representing growth of 5.9% to 7.5%, or 10.1% to 11.7% excluding $48.5 million of transition-of-care revenue from the first half of 2025. Adjusted EBITDA is expected to be $235 million to $240 million, net income $107 million to $110.6 million, and adjusted EPS $2.09 to $2.13.
  • Positive Fourth-Quarter OutlookFourth-quarter revenue is expected to be $344.7 million to $364.7 million, representing growth of 8.3% to 14.6%. Adjusted EBITDA is expected to be $57.9 million to $62.9 million, net income $28.5 million to $32.1 million, and adjusted EPS $0.53 to $0.58.
  • Strong 2027 Membership SetupMost of the more than 85 new clients and 1.3 million new covered lives are expected to launch in the first quarter of 2027, with several hundred thousand lives expected to launch midyear. Once all new clients are live, Progyny anticipates more than 660 clients and 8.3 million covered lives.
  • Progress with Strategic Partnerships and Eligibility DataManagement cited continued momentum from channel partners, particularly Cigna and large regional plans. By year-end, the company expects to have eligibility files covering more than half of its lives.
  • Progyny Select Positioned for Longer-Term GrowthProgyny Select was an immaterial contributor to the most recent selling season, as expected for its first year. Management said it focused on building relationships and infrastructure and continues to expect Select to become a key part of longer-term growth.
  • Expected Moderation of Investment in 2027Management reiterated that investments are expected to taper throughout 2027. It also expects to return to incremental margins as investments in the platform and integrations moderate, although no formal long-term EBITDA margin target has been provided.

PGNY Earnings History

PGNY earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 01, 20272026 (Q4)0.37-0.14――
Nov 04, 20262026 (Q3)0.310.320.15113.33% (+0.17)
Aug 06, 20262026 (Q2)0.340.340.1978.95% (+0.15)
May 07, 20262026 (Q1)0.260.290.1770.59% (+0.12)
Feb 26, 20262025 (Q4)0.150.140.1216.67% (+0.02)
Nov 06, 20252025 (Q3)0.130.150.1136.36% (+0.04)
Aug 07, 20252025 (Q2)0.160.190.1711.76% (+0.02)
May 08, 20252025 (Q1)0.190.170.170.00% (+0.00)
Feb 27, 20252024 (Q4)0.100.120.13-7.69% (-0.01)
Nov 12, 20242024 (Q3)0.140.110.16-31.25% (-0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed